BDO has provided buy-side M&A support to Micro-Tech in connection with their strategic partnership with Creo Medical Group (AIM: CREO), which includes the acquisition of 51% of the issued share capital of Creo Medical S.L.U., a wholly owned subsidiary of Creo Medical Group.

Micro-Tech was founded in 2000 and is the market leader in endoscopic therapy medical devices in China with an approximate market share of 30% of China's endoscopy device market, designing, manufacturing and selling a range of minimally invasive medical instruments. 

The acquisition of a majority interest in Creo Medical S.L.U. will allow Micro-Tech to open new sales channels in Europe and offers further growth potential for its existing business. The resulting partnership with Micro-Tech will support the development of the Creo brand globally and the acceleration of commercialisation of Creo's own products in the APAC region. Creo Medical S.L.U. will continue to sell Creo's own manufactured products in the UK and Europe and will benefit from having access to the wider Micro-Tech product portfolio to re-sell in Europe.
 

"BDO’s advice was instrumental to delivering this successful transaction in a short timeframe. The team's strategic insight and experience helped us navigate this complex, multi-jurisdictional transaction to deliver a great outcome for Micro-Tech. We appreciated their dedication and expertise throughout and look forward to working with BDO on future deals." 
Gareth Bullen, Managing Director, Micro-Tech UK